Pfizer, Eisai announce new licensing agreement for Aricept

Pfizer and Eisai announced a new agreement regarding Aricept (donepezil), which resolves a previously disclosed dispute between the companies. Pfizer and Eisai said they will continue to co-promote the Alzheimer's disease drug in the US, Japan and key markets in Europe, while Pfizer will continue to have an exclusive licence to sell Aricept in the other countries where it has rights.

Under the modified agreement, which follows Eisai’s announcement in May that it would review its Aricept partnership with Pfizer in light of the US drugmaker’s acquisition of Wyeth, Pfizer will maintain its rights in all countries where it currently commercialises the drug until July 2022. However, in Japan, the companies said Pfizer will return the rights to Eisai on December 31, 2012.

The companies also reported a new agreement surrounding Pfizer’s neuropathic pain drug Lyrica (pregabalin), which Eisai will now co-promote with Pfizer in Japan. Lyrica is currently under regulatory review in the country and, if approved, the companies will jointly market the drug until July 2022.

To read more Top Story articles, click here.